US Stock MarketDetailed Quotes
AMLX Amylyx Pharmaceuticals
- 5.540
- -0.200-3.48%
Close Nov 29 13:00 ET
- 5.510
- -0.030-0.54%
Post 17:01 ET
379.76MMarket Cap-1450P/E (TTM)
5.790High5.505Low414.82KVolume5.700Open5.740Pre Close2.32MTurnover0.98%Turnover Ratio7.91P/E (Static)68.55MShares19.94952wk High1.94P/B234.91MFloat Cap1.57552wk Low--Dividend TTM42.40MShs Float41.930Historical High--Div YieldTTM4.97%Amplitude1.575Historical Low5.588Avg Price1Lot Size
About Amylyx Pharmaceuticals Company
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Company Profile
SymbolAMLX
Company NameAmylyx Pharmaceuticals
Listing DateJan 7, 2022
Issue Price19.00
Founded2013
MarketNASDAQ
Employees384
Fiscal Year Ends12-31
Address43 Thorndike Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02141
Phone1-617-682-0917
Websitehttp://www.amylyx.com
Company Executives
- Name
- Position
- Salary
- Justin Klee
- Co-Chief Executive Officer and Director
- 7.42M
- Joshua Cohen
- Co-Chief Executive Officer and Director
- 7.42M
- Dr. Camille L. Bedrosian,M.D.
- Chief Medical Officer
- 2.37M
- Gina M. Mazzariello
- Chief Legal Officer and General Counsel
- 3.01M
- James M. Frates
- Chief Financial Officer and Principal Accounting Officer
- 3.51M
- Dr. George Mclean Milne, Jr,PhD
- Chairman of the Board
- 385.07K
- Dr. Bernhardt G. Zeiher, F.A.C.P.,F.C.C.P.,M.D.
- Director
- --
- Paul Fonteyne, M.S.
- Independent Director
- 342.12K
- Daphne E. Quimi
- Independent Director
- 348.59K
- Karen Firestone
- Independent Director
- 681.15K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data